CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma

NCT07383233 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
CAR T Cell Therapy
Acute Leukemia

Interventions

BIOLOGICAL: CD19/BAFF-R in vivo CAR-T cell intravenous infusion

Sponsor

Qi deng